Evidence map›Paper›PMID 32743602›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection.

Jacob McPadden, Frederick Warner, H Patrick Young, Nathan C Hurley, Rebecca A Pulk, Avinainder Singh, Thomas Js Durant, Guannan Gong, Nihar Desai, Adrian Haimovich and 16 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 21 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Jacob McPaddenDepartment of Pediatrics, Yale School of Medicine, New Haven, CT.
Frederick WarnerDepartment of Pediatrics, Yale School of Medicine, New Haven, CT.
H Patrick YoungCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Nathan C HurleyDepartment of Computer Science and Engineering, Texas A&M University, College Station, TX.
Rebecca A PulkCorporate Pharmacy Services, Yale New Haven Health, New Haven, CT.
Avinainder SinghDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Thomas Js DurantCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Guannan GongCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Nihar DesaiCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Adrian HaimovichYale School of Medicine, New Haven, CT.
Richard Andrew TaylorDepartment of Emergency Medicine, Yale School of Medicine, New Haven, CT.
Murat GunelDepartment of Genetics, Yale University School of Medicine, New Haven, CT.
Charles S Dela CruzDepartment of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT.
Shelli F FarhadianDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT.
Jonathan SinerDepartment of Internal Medicine, Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT.
Merceditas VillanuevaDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT.
Keith ChurchwellYale New Haven Hospital, New Haven, CT.
Allen HsiaoDepartment of Pediatrics, Yale School of Medicine, New Haven, CT.
Charles J TorreDepartment of Laboratory Medicine, Yale University School of Medicine, New Haven, CT.
Eric J VelazquezSection of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
Roy S HerbstYale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT.
Akiko IwasakiDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT.
Albert I KoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT.
Bobak J MortazaviCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Harlan M KrumholzCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Wade L SchulzCenter for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
Yale University · USYale New Haven Hospital · USHoward Hughes Medical Institute · USTexas A&M University · USYale Cancer Center · USYale New Haven Health System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
MEDICAL INFORMATICS RESEARCH TRAINING AT YALET15LM007056 · NLM · YALE UNIVERSITY · PI Mark Bender Gerstein, LUCILA OHNO-MACHADO · 1987 to 2026
$22.2M
NCATS NIH HHS UL1 TR001863NLM NIH HHS T15 LM007056
6 · The paper itself

Abstract

objectiveSevere acute respiratory syndrome virus (SARS-CoV-2) has infected millions of people worldwide. Our goal was to identify risk factors associated with admission and disease severity in patients with SARS-CoV-2.

designThis was an observational, retrospective study based on real-world data for 7,995 patients with SARS-CoV-2 from a clinical data repository.

settingYale New Haven Health (YNHH) is a five-hospital academic health system serving a diverse patient population with community and teaching facilities in both urban and suburban areas. POPULATIONS: The study included adult patients who had SARS-CoV-2 testing at YNHH between March 1 and April 30, 2020. MAIN OUTCOME AND PERFORMANCE MEASURES: Primary outcomes were admission and in-hospital mortality for patients with SARS-CoV-2 infection as determined by RT-PCR testing. We also assessed features associated with the need for respiratory support.

resultsOf the 28605 patients tested for SARS-CoV-2, 7995 patients (27.9%) had an infection (median age 52.3 years) and 2154 (26.9%) of these had an associated admission (median age 66.2 years). Of admitted patients, 2152 (99.9%) had a discharge disposition at the end of the study period. Of these, 329 (15.3%) required invasive mechanical ventilation and 305 (14.2%) expired. Increased age and male sex were positively associated with admission and in-hospital mortality (median age 80.7 years), while comorbidities had a much weaker association with the risk of admission or mortality. Black race (OR 1.43, 95%CI 1.14-1.78) and Hispanic ethnicity (OR 1.81, 95%CI 1.50-2.18) were identified as risk factors for admission, but, among discharged patients, age-adjusted in-hospital mortality was not significantly different among racial and ethnic groups.

conclusionsThis observational study identified, among people testing positive for SARSCoV-2 infection, older age and male sex as the most strongly associated risks for admission and in-hospital mortality in patients with SARS-CoV-2 infection. While minority racial and ethnic groups had increased burden of disease and risk of admission, age-adjusted in-hospital mortality for discharged patients was not significantly different among racial and ethnic groups. Ongoing studies will be needed to continue to evaluate these risks, particularly in the setting of evolving treatment guidelines.

Identifiers

PMID32743602
PMCPMC7386526
OpenAlexW3044635912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.